The company expects to launch more than 20 pivotal late-stage trials this year.

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Pfizer is getting its hands on a promising weight management candidate. The company's recent deal with the U.S. government eliminates a major risk. The stock's valuation looks attractive right now.

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Since November 2021, I've been bullish on Pfizer (PFE) stock, actively arguing that the LOEs they were supposed to go through weren't actually changing the long-term fundamental picture: The firm's ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

Once riding high on the success of its COVID-19 vaccine, Pfizer (PFE) now finds itself in a prolonged slump. Although the ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Dividend stocks can be a great way to generate passive income. Investors must ensure that companies are generating sufficient free cash flow and earnings to cover their dividends, ideally with the ...

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in market value. The ...